UBS O'Connor’s Aurinia Pharmaceuticals AUPH Stock Holding History

UBS O'Connor’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-400,000	Closed	-$2.94M	–	389
2017 Q1	$2.94M	Buy	+400,000	New	+$1.85M	0.05%	274

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

UBS O'Connor's AUPH Position: Q2 2017 in Review

UBS O'Connor sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2017, closing a stake of 400,000 shares — an estimated $2.94M sold.

UBS O'Connor first reported a position in AUPH in Q1 2017 and held it in 1 quarter. The position peaked at $2.94M in Q1 2017. 65 funds tracked by Wall St. Rank hold AUPH as of Q2 2017.

UBS O'Connor reported no remaining Aurinia Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
UBS O'Connor sold 400,000 Aurinia Pharmaceuticals shares in Q2 2017, an estimated $2.94M.
UBS O'Connor first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 1 quarter.
UBS O'Connor's Aurinia Pharmaceuticals position peaked at $2.94M in Q1 2017.
65 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2017.

Based on UBS O'Connor's 13F filing for Q2 2017, filed 14 Aug 2017.